The Indian pharma market (IPM) is valued at Rs 6,305 crores in October 2013. It has grown at -1.70 per cent in October 2013. Zydus Cadila is the third biggest company in IPM versus fourth of last month but maintained fourth rank amongst corporates.
Amongst the top 10, Sun Pharma was at 15.1 per cent followed by Zydus at 2.7 per cent. 35 corporates have crossed the growth of IPM for the month of October 2013 amongst top 50. Amongst the top 50 corporates, Corona Remedies has the highest growth of 69.4 per cent followed by Biocon at 55.4 per cent and Meyer at 27.4 per cent.
With bonus units at full value (Val in Crs) | ||||||||
Rank | MAT Sep -13 | Sep-13 | ||||||
CORPORATE | MAT | MTH | Val (Cr) | MS% | GR% | Val (Cr) | MS% | GR% |
| IPM | 72381 | 100.00 | 5.1 | 6305 | 100.00 | -1.7 | ||
| Abbott + Abbott HC + Novo | 1 | 1 | 4815 | 6.65 | 0.8 | 413 | 6.54 | -6.1 |
| Sun Pharma | 2 | 2 | 3821 | 5.28 | 17.2 | 346 | 5.49 | 15.1 |
| Cipla | 3 | 3 | 3658 | 5.05 | 4.6 | 320 | 5.08 | 0.4 |
| Zydus + Biochem | 4 | 4 | 3247 | 4.49 | 14.0 | 284 | 4.50 | 2.7 |
| Glaxo | 5 | 8 | 2941 | 4.06 | -8.7 | 191 | 3.03 | -35.5 |
| Ranbaxy | 6 | 5 | 2917 | 4.03 | 2.0 | 235 | 3.72 | -14.5 |
| Mankind | 7 | 7 | 2605 | 3.60 | 7.2 | 228 | 3.62 | -3.9 |
| Alkem + Cachet + Indchemie | 8 | 6 | 2532 | 3.50 | 8.1 | 233 | 3.70 | 0.4 |
| Lupin | 9 | 10 | 2179 | 3.01 | 6.4 | 188 | 2.98 | -1.7 |
| Pfizer + Wyeth | 10 | 14 | 2100 | 2.90 | -3.6 | 162 | 2.57 | -22.3 |
| Emcure + Zuventus | 11 | 9 | 2022 | 2.79 | 14.6 | 190 | 3.01 | 13.3 |
| Macleods | 12 | 12 | 1860 | 2.57 | 7.5 | 164 | 2.61 | -5.4 |
| Intas | 13 | 13 | 1837 | 2.54 | 12.8 | 163 | 2.58 | 7.5 |
| Aristo | 14 | 11 | 1707 | 2.36 | 6.0 | 166 | 2.64 | 1.7 |
| Dr. Reddys | 15 | 16 | 1612 | 2.23 | 8.6 | 138 | 2.18 | 3.3 |
| Sanofi-Aventis + Universal | 16 | 18 | 1532 | 2.12 | 1.4 | 126 | 1.99 | -6.0 |
| Glenmark | 17 | 15 | 1512 | 2.09 | 13.6 | 146 | 2.32 | 17.5 |
Amongst the 11-20 ranked companies, Glenmark has shown a high growth at 17.5 per cent followed by Torrent and Emcure at 13.3 per cent and USV at 10.9 per cent. Amongst upcoming corporates, Corona Remedies has grown at 69.4 per cent, Akument at 20.4 per cent and Eris at 18.3 per cent.
Amongst the top 50 in MNCs, Allergan grew the highest at 14.6 per cent, followed by Astra Zeneca at 7.6 per cent and MSD at 3.4 per cent. Novartis and Merck were better than IPM growths.
The DPCO 2013 containing molecules market was at -17.9 per cent whereas the non DPCO market grew by meagre 0.9 per cent resulting in an overall growth of -1.7 per cent for October 2013. The DPCO 2013 portfolio for GSK de-grew at 48.9 per cent and Ranbaxy de-grew by 31.9 per cent, whereas Sun Pharma had the least impact with its DPCO 2013 portfolio de-growing at four per cent.
The market has witnessed negative growths in the units as well in both the categories.
Super Group | MAT Oct 13 | GR% | Mth Oct 13 | GR% |
| IPM | 72381 | 5.1 | 6305 | -1.7 |
| ANTI-INFECTIVES | 12484 | 0.9 | 1080 | -15.1 |
| CARDIAC | 8927 | 8.7 | 771 | 6.9 |
| GASTRO INTESTINAL | 8225 | 4.6 | 699 | 2.0 |
| VITAMINS / MINERALS / NUTRIENTS | 6393 | 3.6 | 555 | -2.1 |
| RESPIRATORY | 5592 | 5.6 | 517 | -3.8 |
| PAIN / ANALGESICS | 5226 | 3.0 | 457 | -3.3 |
| ANTI DIABETIC | 5007 | 10.0 | 448 | 10.4 |
| GYNAECOLOGICAL | 4639 | 3.2 | 380 | -3.3 |
| NEURO / CNS | 4494 | 8.5 | 388 | 4.4 |
| DERMA | 3882 | 7.6 | 349 | 6.4 |
| OPHTHAL / OTOLOGICALS | 1307 | 6.8 | 114 | 4.7 |
| HORMONES | 1241 | 6.5 | 107 | -6.3 |
| ANTI-NEOPLASTICS | 973 | 24.3 | 88 | 27.9 |
| OTHERS | 935 | 3.7 | 81 | 0.5 |
| BLOOD RELATED | 875 | 2.6 | 73 | -1.9 |
| VACCINES | 841 | -2.6 | 61 | -13.3 |
| ANTI MALARIALS | 588 | -5.2 | 74 | -15.1 |
| SEX STIMULANTS / REJUVENATORS | 424 | 10.3 | 35 | 6.9 |
| STOMATOLOGICALS | 327 | 6.7 | 29 | 8.6 |
From therapy perspective , 10 therapies have outgrown the IPM growth. The anti-infective market has a de-growth of -15.1 per cent whereas respiratory market is at -3.8 per cent growth. The anti-diabetic market grew at 10.40 per cent and cardiac at 6.9 per cent in chronic business. Stomatologicals grew by 8.6 per cent, whereas derma market was at 6.4 per cent. Bonus in the anti-infective segment de-grew by 15.7 per cent, whereas in respiratory market it was -9.6 per cent.
From regional perspective 12 regions have outgrown the IPM growth. Kerala grows highest at seven per cent whereas Gujarat has registered 3.6 per cent. Tamil Nadu de-grew at 6.2 per cent and Andhra Pradesh rest de-grew at 5.2 per cent. 12 regions have had negative growths in September 2013.
The biggest molecule Amoxycillin + Clavulanic de-grew by 13.6 per cent, whereas Cefixime de-grew at 17.5 per cent. Paracetamol de-grew at 21.3 per cent and Azithromycin at 20.5 per cent. The markets of vitamin D grew by 50.1 per cent, Glimepiride + Metformin grew at 39.4 per cent, Rosuvastain by 19.3 per cent and Telmisartan grew by 17.4 per cent.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
- Advertisement -
